Year: 2019
Type: review
Abstract: As the leading causes of human disability and mortality, neurological diseases affect millions of people worldwide and are on the rise. Although the general roles of several signaling pathways in the pathogenesis of neurodegenerative disorders have so far been identified, the exact pathophysiology of neuronal disorders and their effective treatments have not yet been precisely elucidated. This requires multi-target treatments, which should simultaneously attenuate neuronal inflammation, oxidative stress, and apoptosis. In this regard, astaxanthin (AST) has gained growing interest as a multi-target pharmacological agent against neurological disorders including Parkinson's disease (PD), Alzheimer's disease (AD), brain and spinal cord injuries, neuropathic pain (NP), aging, depression, and autism. The present review highlights the neuroprotective effects of AST mainly based on its anti-inflammatory, antioxidative, and anti-apoptotic properties that underlies its pharmacological mechanisms of action to tackle neurodegeneration. The need to develop novel AST delivery systems, including nanoformulations, targeted therapy, and beyond, is also considered.
Source: Molecules
Language: English
Subfield: Neurology
Field: Neuroscience
Domain: Life Sciences
Keywords: astaxanthin, neuroprotection, neurodegenerative diseases, Parkinson's disease, Alzheimer's disease, brain injury, spinal cord injury, neuropathic pain, oxidative stress, neuroinflammation, apoptosis, anti-inflammatory activity, antioxidant activity, multi-target therapy, drug delivery systems, nanoformulations, depression, autism spectrum disorder
Open Access status: gold
Estimated APC paid: $1,824
OpenAlex ID: W2963532412
